Acute Myeloblastic Leukemia with Maturation

Search Trials
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
trebananibcytarabinelaboratory biomarker analysispharmacological study
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Status:
Terminated
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Intervention(s):
decitabinepharmacological studylaboratory biomarker analysis
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Withdrawn
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
arsenic trioxidelaboratory biomarker analysis
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
pravastatin sodiumidarubicincytarabinelaboratory biomarker analysis
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
lenalidomidemitoxantrone hydrochlorideetoposidecytarabine

Connect. Empower. Inspire.